Navigation Links
RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
Date:1/14/2014

d on the mRNA that controls production of this protein.

RXi's sd‑rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. These hybrid oligonucleotide molecules combine the beneficial properties of conventional RNAi and antisense technologies.  This allows sd‑rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTCQX: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great  promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, including future expectations regarding our NASDAQ listing, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks th
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Wash. , July 31, 2014   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... media and precision thermal shipping products for ... second quarter 2014 financial results will be released on ... host a conference call and live webcast at 4:30 ...
(Date:7/31/2014)... July 31, 2014 Boston’s Adult Stem ... flush with innovative adult stem cell biotechnologies. Currently ... and has three additional patent applications currently under examination ... patented inventions address two of the most vexing problems ... Adult stem cells are difficult to identify; and ...
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SNY) today announced that the Companies intend to use ... disease priority review voucher in connection with the Biologics ... voucher entitles the holder to designate a BLA for ... from the filing date instead of the standard 10-month ...
(Date:7/30/2014)... 30, 2014 A study presented at ... and efficacy of CSL Behring,s C1 Inhibitor (C1-INH) ... in highly sensitized patients. C1-INH is a human ... system. The study shows that post-transplant ... the levels of complement components 3 and 4, ...
Breaking Biology Technology:BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... Baltimore Convention Center - September 21-23, 2009 ... summit will attract more than 1,200 experts from more than 25 ... 100 speakers, including governors, federal officials, and top researchers and scientists ... human-interest stories. This is your chance to meet and talk ...
... Aug. 11 ValGenesis, Inc., a leading provider ... availability of Microsoft SharePoint Server integration with the ... productivity specifically for regulated Pharmaceuticals, Biotech and Medical ... access, retrieval and storage of corporate validation data ...
... , NEWTON, Mass., Aug. 11 Microfluidics International Corporation ... quarter ended June 30, 2009. , , ... quarter accomplishments: , , Achieved positive ... Delivered strong bookings of $6.6 million with ...
Cached Biology Technology:World Stem Cell Summit to Be Held in Baltimore 2ValGenesis, Inc. Announces Integration of ValGenesis Solution with Microsoft SharePoint Server 2Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 2Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 3Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 4Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 5Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 6Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 7Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 8Microfluidics International Corporation Announces Second Quarter 2009 Financial Results 9
(Date:7/31/2014)... July 31, 2014 Biometrics industry ... innovative smart technologies; companies turn towards digital currency: NXT-ID, ... ), Amazon.com Inc. (NASDAQ: AMZN ), Facebook ... GOOG ) and Microsoft Corporation (NASDAQ: MSFT) ... on the growing m-commerce market, announces a video featuring ...
(Date:7/30/2014)... York University is paving the way for a ... and military troops exposed to poisonous chemicalsparticularly those ... article in the current issue of the journal ... organophosphates, which are compounds commonly used in pesticides ... by NYU School of Engineering Associate Professor of ...
(Date:7/30/2014)... Chemical Society (ACS) announced today that David L. Kaplan, ... Biomaterials Science & Engineering as editor-in-chief. With the ... new journal will feature high-quality research in the rapidly ... naturally derived materials that interact with living or biological ... reflects the tremendous growth in the field of biomaterials ...
Breaking Biology News(10 mins):Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 3Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 4Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 6Engineering a protein to prevent brain damage from toxic agents 2ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... is threatening the time-honored transmission of plant knowledge from ... and nutrition. In a novel study published online this ... Sciences, researchers report that parents, and especially mothers, who ... have healthier children, independent of other factors such as ...
... National Museum of Natural History in Washington, D.C., have ... of what they regard as one of the weirdest ... that the organism was a fungus, the scientists report ... published by the Geological Society of America. Called Prototaxites ...
... long been known that UV light can damage DNA, reducing ... resulting in the development of skin cancers. However, not much ... altered upon exposure to UV light. Now a group of ... changes in the mechanical properties of DNA upon irradiation with ...
Cached Biology News:Mother knows best: Plant knowledge key to childhood health in remote Amazon 2Prehistoric mystery organism verified as giant fungus 2Prehistoric mystery organism verified as giant fungus 3Prehistoric mystery organism verified as giant fungus 4Stretching DNA to the limit 2